Clinical dilemmas in heart failure: Weighing the balance of RAASi and hyperkalaemia

If you are attending Heart Failure 2022 live or online, you are invited to attend this EBAC-accredited symposium.

Saturday, May 21, 2022: 14:55 – 15:40 hrs CEST

Educational Objectives

• Understand the impact of new guidelines on reaching recommended RAASi doses and the impact on outcomes in HF patients
• Discuss the unmet medical needs and their consequences with the current hyperkalaemia treatment options
• Understand the impact and significance of long-term RAASi treatment, at maximum tolerated guideline recommended doses in HF patients;
• Discuss new directions in hyperkalemia management that could achieve better outcomes in HF patients

Agenda

• Introduction: Guidelines, RAASi and hyperkalaemia: The clinical dilemmas in heart failure - Andrew Coats, MD - Warwick, United Kingdom
• Hyperkalaemia in heart failure: Why should we care? - Clara Bonanad, MD - Valencia, Spain
• Potassium binding as RAASi enabling therapy: Applying recent insights into practice - Aaron Wong, MD - Bridgend, Wales, United Kingdom
• Panel discussion: Potassium binding in practice, when and how to start? All faculty

For more information, please visit the ESC Heart Failure website.

CME Accreditation

This programme is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) for 1 hour of external CME credit(s). Each participant should claim only those hours of credit that have actually been spent in the educational activity. The Accreditation Council for Continuing Medical Education (ACCME®) and EBAC have recognized each other’s accreditation systems as substantially equivalent.

Funding

This symposium is supported by an unrestricted educational grant from AstraZeneca.